DIRC2 Polyclonal Antibody, Cy7 Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-8278R-Cy7-100uL |
| Product Name | DIRC2 Polyclonal Antibody, Cy7 Conjugated |
| Applications |
WB
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Reactivity | Human |
| Predicted Reactivity | Mouse, Rat, Dog, Sheep, Pig, Horse, Rabbit |
| Specifications | |
| Conjugation | Cy7 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human DIRC2 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 84925 |
| Subcellular location | Cytoplasm, Cell membrane |
| Synonyms | Disrupted in renal carcinoma protein 2; DIRC 2; Disrupted in renal cancer protein 2; Disrupted in renal carcinoma 2; FLJ14784; NP_116228; RCC 4; RCC4; Renal cell carcinoma 4; DIRC2_HUMAN. |
| Background | Belonging to the major facilitator superfamily, DIRC2 (disrupted in renal carcinoma protein 2) is a 478 amino acid multi-pass membrane protein that is primarily expressed in kidney proximal tubular cells. The genes encoding DIRC2 and DIRC3 are located at a translocation breakpoint which occurs frequently in individuals affected by familial renal cell carcinoma. Fusion transcripts that result from these translocations may affect normal protein function. This evidence suggests that, due to its chromosomal location, deregulation of the DIRC2 gene may cause haploinsufficiency and therefore result in the onset of tumor growth. There are two isoforms of DIRC2 which are produced as a result of alternative splicing events. |
| Application Dilution | |
| WB | 1:300-5000 |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |
Frequently asked questions
Which applications is DIRC2 Polyclonal Antibody, Cy7 Conjugated (bs-8278R-Cy7) validated for, and at what dilution?
bs-8278R-Cy7 is validated for WB (1:300-5000); IF(IHC-P) (1:50-200); IF(IHC-F) (1:50-200); IF(ICC) (1:50-200). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
Which species does DIRC2 Polyclonal Antibody, Cy7 Conjugated (bs-8278R-Cy7) react with?
Tested reactivity: Human. Predicted reactivity (expected from sequence homology but not yet tested): Mouse, Rat, Dog, Sheep, Pig, Horse, Rabbit.
How should bs-8278R-Cy7 be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise DIRC2 Polyclonal Antibody, Cy7 Conjugated (bs-8278R-Cy7)?
KLH conjugated synthetic peptide derived from human DIRC2
What are the excitation and emission wavelengths of the Cy7 conjugate (bs-8278R-Cy7)?
Cy7 on bs-8278R-Cy7: excitation / emission 743nm/767nm.